UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

EJHaem, 2020-07, Vol.1 (1), p.170-180

2020

Volltextzugriff (PDF)

New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs

Seminars in oncology, 2018-10, Vol.45 (5-6), p.291-302

2018

Volltextzugriff (PDF)

Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index

Neoplasma, 2022-12, Vol.69 (6), p.1466-1473

2022

Volltextzugriff (PDF)

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

Leukemia & lymphoma, 2017-03, Vol.58 (3), p.601-613

2017

Volltextzugriff (PDF)

What is new in the treatment of peripheral T-cell lymphomas in the Czech Republic

Transfuze a hematologie dnes, 2023-12, Vol.29 (4)

2023

Volltextzugriff (PDF)

Changes in quality of life in oncological patients in remission after participation in an interventional exercise - respiratory training

Tělesná kultura (Olomouc), 2019-07, Vol.41 (2), p.69-73

2019

Volltextzugriff (PDF)

Radiotherapy in early stage follicular lymphoma: is it really the gold standard?

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2999-3000

Janikova, Andrea

2015

Volltextzugriff (PDF)

Pohybová aktivita jako účinný prostředek nefarmakologické péče v onkologii

2021

Volltextzugriff (PDF)

Chemotherapy-induced polyneuropathy

Neurologie pro praxi, 2017-03, Vol.18 (1), p.25-31

2017

Volltextzugriff (PDF)

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

The Lancet. Haematology, 2015-04, Vol.2 (4), p.e166-e174

2015

Volltextzugriff (PDF)

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world

European journal of haematology, 2022-08, Vol.109 (2), p.162-165

2022

Volltextzugriff (PDF)

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

Annals of hematology, 2023-01, Vol.102 (1), p.107-115

2023

Volltextzugriff (PDF)

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients

Leukemia & lymphoma, 2019-05, Vol.60 (6), p.1420-1428

2019

Volltextzugriff (PDF)

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

Leukemia & lymphoma, 2019-02, Vol.60 (3), p.675-684

2019

Volltextzugriff (PDF)

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Annals of hematology, 2019-08, Vol.98 (8), p.1961-1972

2019

Volltextzugriff (PDF)

Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry

Leukemia & lymphoma, 2016-12, Vol.57 (12), p.2777-2783

2016

Volltextzugriff (PDF)

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database

Annals of hematology, 2018-04, Vol.97 (4), p.669-678

2018

Volltextzugriff (PDF)

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group

Leukemia research, 2018-10, Vol.73, p.29-38

2018

Volltextzugriff (PDF)

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

Leukemia & lymphoma, 2015-08, Vol.56 (8), p.2350-2356

2015

Volltextzugriff (PDF)

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry

Leukemia & lymphoma, 2019-02, Vol.60 (3), p.748-755

2019

Volltextzugriff (PDF)

Potential loss of prognostic significance of minimal residual disease assessment after R‐CHOP‐based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

Hematological oncology, 2018-12, Vol.36 (5), p.773-778

2018

Volltextzugriff (PDF)

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

Annals of hematology, 2020-07, Vol.99 (7), p.1583-1594

2020

Volltextzugriff (PDF)

Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

Hematological oncology, 2018-02, Vol.36 (1), p.110-115

2018

Volltextzugriff (PDF)

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

Leukemia & lymphoma, 2014-04, Vol.55 (4), p.802-810

2014

Volltextzugriff (PDF)

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

Leukemia & lymphoma, 2016-05, Vol.57 (5), p.1094-1103

2016

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

KollektionEZB-FREE-00999 freely available EZB journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(35)
Berichte
(2)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Hematology
(25)
Oncology
(23)
Humans
(22)
Female
(17)
Middle Aged
(17)
Adult
(15)
Aged
(15)
Male
(15)
Prognosis
(13)
Rituximab
(13)
Treatment Outcome
(13)
Follicular Lymphoma
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Neoplasm Staging
(8)
Retrospective Studies
(8)
Aged, 80 And Over
(6)
Follow-Up Studies
(6)
Lymphoma
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs

Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

What is new in the treatment of peripheral T-cell lymphomas in the Czech Republic

Changes in quality of life in oncological patients in remission after participation in an interventional exercise - respiratory training

Radiotherapy in early stage follicular lymphoma: is it really the gold standard?

Pohybová aktivita jako účinný prostředek nefarmakologické péče v onkologii

Chemotherapy-induced polyneuropathy

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry

Potential loss of prognostic significance of minimal residual disease assessment after R‐CHOP‐based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)

Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

Aktive Filter

Suchergebnisse filtern